Pre-treatment of these mice with recombinant human soluble complement receptor-1 (rsCR1) significantly reduced the number of immune cells infiltrating the lung, minimised deposition of C3 and C5b-9 in lung vessels and decreased pulmonary oedema (29). This evidence concerns the gene CR1 and pulmonary edema.